6 research outputs found
Free language-learning platform for boosting basic english sentence structure among students of tenth grade at EHB Veinticuatro de Julio, Santa Elena. province of Santa Elena. school year 2015-2016.
No full textThe purpose of the research is focused on the implementation of new strategies for teaching such as the free language-learning platforms to improve Basic English writing. Based on studies done in different countries such as the United States, Guatemala, and East Africa, the author applies the proposal of the academic use of virtual platforms to improve the deficiency in the Basic English sentence structure at escuela de educación básica Veinticuatro de Julio. This work is justified by the results based on observations and tests where students do not reach A2 level in writing according to Common European Framework of Reference for Language, the research methodology was qualitative and quantitative with approaches on action research and grounded theory which leads to enact new educational paths that go hand in hand with the update of learning. The implementation of the free virtual platform benefited the majority of the students. It was obtained positive changes in educational goals in a short-term performance; it is worth mentioning that the research produced good results but also gave standard results which reflect the little interest on the language by the students. It gives emphasis to reformulate ways of teaching and change the traditional teaching for an update in the teachinglearning process where the teachers can use images, videos, or proper use of virtual platforms, encouraging improvement in education and adapting of technology in classes. The content of the virtual platform is suitable for the English book of the tenth grade issued by the Ministry of Education, it contains online activities such as; images, videos, and audios to correct handling and boost the basic English sentence structure. As a result, working with this strategy of teaching will contribute with positive effects on the development of productive skills of the students
La discriminación al indígena ecuatoriano en la obra El Cojo Navarrete de Enrique Terán.
No full textEl presente proyecto de investigación se basó en la discriminación al indígena ecuatoriano a través de la obra El Cojo Navarrete del autor Enrique Terán, con el objetivo de analizar los tipos de discriminación y violencia hacia los indígenas del país. Se muestra un punto de vista de cómo los indígenas eran tratados en la época liberalista. La metodología pertenece al enfoque cualitativo, nivel descriptivo y la modalidad de investigación bibliográfico-documental, el diseño de investigación narratológico que permitió rescatar sucesos, hechos, historias de vida y experiencia de los personajes de la obra. Entre los resultados se resalta lo diversos tipos de discriminación racial, político o ideológico, étnico o nacional, por discapacidad y nivel socioeconómico. La
conclusión más relevante menciona como los actos de discriminatorios se presentan en diferentes fragmentos de la obra acompañado por cada uno de sus tipos de discriminación y son una causa para generar actos de violencia al indígena. La obra se distingue por su género narrativo utilizando el realismo para dar una explicación de los hechos que sucedían en la época. Se recomienda analizar la violencia política e ideológica por el hecho de generar varios hilos de investigación que permiten comprender el movimiento Alfarista y las represalias que llevaban en la época. Por último, como propuesta de este proyecto, se realizó un ensayo académico con la finalidad de describir y criticar a la discriminación dentro de la sociedad ecuatorianaThis research was based on the discrimination of Ecuadorian indigenous through the book El Cojo Navarrete by the author Enrique Terán, with the objective to analyze the types of discrimination and violence towards the indigenous of the country. It shows a point of view of how indigenous were treated in the liberal era. The methodology belongs to a qualitative focus, descriptive level, and modality of investigation documental bibliographic, the narratology investigation design that allows to rescue events, facts, life stories and experiences of the characters in the book. Among the results highlight the different types of racial discrimination, political or ideological, ethnic, or national, by incapacity or socioeconomic level. The most relevant conclusion
mentions how the acts of discrimination in different fragments of the book are joined by each type of discrimination and are a cause to generate acts of violence against indigenous. The book is distinguished because of the narrative genre using realism to explain facts that happen in the time. It is recommended to analyze the political and ideological violence because generates various threads of investigation that allow us to comprehend the Alfarista movement and the reprisals that had that time. Finally, as a proposal for this project, was made an academic essay with the purpose to describe and criticize discrimination inside Ecuadorian societ
Retos, avances y reflexiones transdisciplinares desde contextos educativos diversos
No full textLa publicación de las ponencias que conformaron el V Congreso Internacional de Educación de la Universidad Nacional de Educación, titulado Retos, avances y reflexiones transdisciplinares desde contextos educativos diversos, ofrece una visión comprensiva y multifacética de la educación contemporánea. A través de ocho ejes temáticos, entre los que se incluye la formación integral y el desarrollo profesional, la teoría y la práctica en la formación profesional docente, la relación entre sociedad y escuela, la gestión educativa y las tecnologías para la educación, esta recopilación busca contribuir al conocimiento académico sobre la educación y, al mismo tiempo, ser fuente de información e inspiración para educadores, investigadores y todas aquellas personas interesadas en el desarrollo educativo
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
No full textInternational audienceBACKGROUND:Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.METHODS:This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.FINDINGS:Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).INTERPRETATION:Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
No full textBackground Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. Methods This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0.90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants. Findings Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0.72, 95% CI 0.57-0.90, p=0.0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0.54 95% CI 0.35-0.82, p=0.0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0.86, 95% CI 0.69-1.08, p=0.19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0.67, 95% CI 0.45-1.00, p=0.05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1.61, 95% CI 1.12-2.31, p=0.0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1.68, 95% CI 1.17-2.40; p=0.0043). Interpretation Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding.peer-reviewe
